Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
or suppressing p27Kip1 degradation
#PharmaNews #PharmaResults #EarningsUpdate #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ Gland Pharma FY25 Results: Strong Margins, 31 Product Launches Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
Each weekly dose adds to the building concentration until a plateau is reached where elimination matches intake
Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease
tissue necrosis is exceedingly rare
US$ 28.02
US$ 20.09
US$ 24.60
